2月8日，信达生物与礼来达成合作，共同推进肿瘤及免疫领域创新药全球研发，信达生物将获3.5亿美 元首付款及最高约85亿美元里程碑付款及销售分成。 无独有偶，2月5日，复宏汉霖与日本卫材签订协议，授予其在日本区域内斯鲁利单抗注射液用于肿瘤适 应症治疗的开发、生产及商业化权利，交易总金额近4亿美元。 回顾2025年，中国创新药对外授权（License-out）交易总金额突破1300亿美元，中国医药企业的国际化 进程已逐步成为行业当前发展的主旋律。然而，在推动企业"走出去"的实践中，呈现出显著的分层特征 与结构性不均衡。一方面，以华润医药、百济神州、复星医药等为代表的龙头企业已具备较为扎实的国 际化基础；另一方面，大量中小企业则因国内市场竞争高度内卷及集采带来的经营压力，将海外市场视 为新的生存机会与发展路径。 突破核心瓶颈 合规能力是国际化的核心前提。对于原料药、中间体企业而言，过去凭借成本与产能优势尚可维持出 口，但若要进入生物医药、高端医疗器械乃至医保报销体系，则必须满足ICH、PIC/S、FDA、EMA等 国际通行的法规与质量标准。值得肯定的是，中国已正式加入ICH，并正在积极申请加入PIC/S。后者 一旦 ...

Core Viewpoint - Luoketech is preparing for an IPO on the Hong Kong Stock Exchange, aiming to become the first publicly listed company focused on AI smart locks, with significant backing from major investors like Baidu and Xiaomi [1][2][7]. Company Overview - Founded in 2014, Luoketech specializes in smart locks and comprehensive security solutions for homes and communities, achieving the highest global shipment volume of vein recognition smart locks [2][5]. - The company was previously known as Yunding Technology and rebranded in 2022, focusing on smart security with its core product being the "Lockin Luoke" smart door lock [4]. Product Development - Luoketech has pioneered several innovations in smart lock technology, including the first integrated apartment smart lock system in 2015 and the first mass-produced vein recognition smart lock in 2021 [4]. - The company plans to evolve beyond hardware manufacturing to become an "AI home security steward," integrating AI algorithms and sensing technologies into its products [4]. Market Position - According to Frost & Sullivan, Luoketech is the first company to achieve large-scale production of vein recognition smart locks, with a projected market share of 10.5% in 2024 [5]. - The company ranks fourth globally in smart lock shipments, holding a market share of 2.6% [5]. Financial Performance - In 2023, Luoketech reported revenues of 1.01 billion RMB, with projections of 1.09 billion RMB for 2024 and an 11.5% increase in revenue to 773.58 million RMB in the first three quarters of 2025 compared to the same period in 2024 [6]. - The company's profit for 2023 was 14.03 million RMB, increasing to 53.11 million RMB in 2024, with a profit of 31.98 million RMB in the first three quarters of 2025 [6]. Business Structure - Luoketech's revenue is primarily derived from three segments: ODM (Original Design Manufacturing), proprietary brand consumer products, and commercial solutions [5]. - The ODM business contributed 476 million RMB in revenue for the first three quarters of 2025, accounting for 61.6% of total revenue, while proprietary brand consumer product revenue decreased to 159 million RMB [5]. Shareholder Composition - The founder, Chen Bin, controls 30.35% of the company, with Baidu being the largest external investor at 18.43% [8][9]. - Other notable investors include Shunwei Capital and Fosun Group, indicating strong backing from prominent venture capital firms [8]. Sales Channels - Luoketech markets its proprietary brand "Luoke" through major e-commerce platforms, partner networks, and offline stores, while also providing ODM services to brands like Xiaomi [10]. - The company aims to expand its reach, with a target shipment volume of 1.3 million units by 2025, covering over 50 countries and regions [10].

Core Insights - The meeting between Jiangsu Province Governor Liu Xiaotao and Fosun International Chairman Guo Guangchang highlights the ongoing collaboration and investment opportunities in Jiangsu, focusing on sectors like biomedicine, healthcare, cultural tourism, consumption, and finance [1] Group 1: Investment and Economic Development - Fosun has invested over 100 billion yuan in Jiangsu, establishing a strong presence across multiple industries [2] - The company aims to deepen its business cooperation in Jiangsu, leveraging its technological and talent advantages to meet local development needs [1][2] Group 2: Biomedicine Sector - Fosun Pharma has developed a collaborative industrial ecosystem in Jiangsu, with multiple innovative drugs and biosimilars launched in the past five years [2] - The company plans to maintain its R&D investment during the 14th Five-Year Plan, focusing on areas such as metabolism, hematology, oncology, respiratory, autoimmune, and ophthalmology [2] Group 3: Cultural Tourism and Consumer Sector - The Taicang Alps International Resort, developed by Fosun Tourism, has become a benchmark for the "ice and snow economy" in the Yangtze River Delta, attracting over 2 million visitors since its opening in November 2023 [3] - The Club Med resort in Nanjing has also gained popularity since its opening in October 2023, while the Suzhou Songhelou restaurant is expanding internationally with plans to open its first overseas location in London by April 2025 [3] Group 4: Collaboration in Emerging Technologies - Fosun is engaging in extensive collaborations with various regions in Jiangsu through investment funds, focusing on cutting-edge fields such as embodied intelligence, semiconductors, and new materials [3]

Macro and Strategy Research - In January 2026, the central bank's liquidity net injection reached 1.2 trillion yuan, an increase of nearly 400 billion yuan compared to December 2025, indicating a supportive stance on liquidity [3] - The issuance of interest rate bonds in January 2026 totaled 2.7 trillion yuan, a year-on-year increase of over 600 billion yuan, with significant growth in government bonds, local bonds, and policy financial bonds [4] - The bond market outlook suggests that if the liquidity remains stable, interest rate bonds may show a strong oscillation pattern, with a focus on 3-year bonds and ultra-long-term bonds for potential gains [5] Industry Research - The pharmaceutical and biotechnology industry is seeing a concentration of performance forecasts, with key developments including the approval of new drugs and significant partnerships among companies [10][11] - The SW pharmaceutical and biotechnology index saw a decline of 0.97% in the week of January 30 to February 5, 2026, with the industry’s price-to-earnings ratio at 51.01 times, reflecting a 261% premium over the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, as well as monitoring companies that are expected to show a turnaround in performance [12]

Core Insights - The article highlights the fundraising activities of various investment funds in January 2026, with a total of 17 fundraising events amounting to over 270 billion RMB [2]. Fundraising Activities - Hengxu Capital completed the first closing of its fourth flagship fund, raising over 2 billion RMB, with a target final closing of 3.5 billion RMB [5][7]. - Dongfang Jiafu National SME Development Sub-Fund successfully completed its first closing of 1.6 billion RMB, with a total target of 2 billion RMB, focusing on advanced manufacturing, new materials, and health sectors [8][9]. - Zhangzhou Capital Operations Group and CICC established a healthcare fund with a total scale of 1 billion RMB, targeting traditional Chinese medicine and biomedicine [10][11]. - China Resources Capital launched a 1 billion RMB fund focused on chemical innovation drugs and high-end medical devices [12]. - Caitong Capital's two funds completed expansion, raising over 2.4 billion RMB to support the development of Taizhou Bay New Area [13]. - Kaibo Capital's Kaibo Nord Energy Storage Fund completed registration with a scale of 400 million RMB, focusing on independent energy storage projects [14][15]. - Deth Capital initiated a 500 million RMB fund aimed at the cultural and film sectors [18]. - The Baiyin Specialty Industry Fund, managed by Jincheng Capital, successfully registered with a scale of 200 million RMB, focusing on local specialty industries [19][20]. - Guangzhou Industrial Control Group launched a 1 billion RMB fund to support early-stage technology companies [21]. - Hushan Capital's new fund focusing on AI and semiconductor industries completed its first closing at 400 million RMB [22]. - Hubei Port and Shipping Development Fund completed expansion, reaching a scale of 2.8 billion RMB [24]. - Luxin Venture Capital initiated a 1 billion RMB fund targeting the artificial intelligence sector [26][27]. - Electric Science Investment established a 2 billion RMB electronic basic industry fund [28]. - Shangcheng Capital launched a 10 billion RMB fund to support AI and embodied intelligence industries [29]. - Beigong Investment and Jizhi Future established a 200 million RMB venture capital fund focusing on AI and new information technology [30]. - SPD Bank launched the "Puchuang Huazhang" science and technology direct investment fund with a scale of 500 million RMB [32][33]. - The "Golden Seed" fund for university student entrepreneurship was established with a scale of 45 million RMB [34][35].

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - AbbVie has submitted regulatory applications for its JAK inhibitor Rinvoq for the treatment of non-segmental vitiligo to both the FDA and EMA, based on positive results from the Phase 3 Viti-Up clinical study [5]. - The pharmaceutical sector showed a slight increase of +0.18% on February 5, 2025, outperforming the CSI 300 index by 0.78 percentage points, ranking 8th among 31 sub-industries [4]. - Among sub-industries, hospitals (+0.81%), offline pharmacies (+0.74%), and medical R&D outsourcing (+0.49%) performed well, while other bioproducts (-0.99%), vaccines (-0.44%), and pharmaceutical distribution (-0.25%) lagged behind [4]. Sub-industry Summary - Chemical pharmaceuticals: No rating [3] - Traditional Chinese medicine production: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other pharmaceutical industries: Neutral [3]

事件 群益证券发布研报称，预计复星医药（600196）(02196)2025-2027年分别实现净利润33.2亿元、46.8亿 元、47.7亿元，YOY分别+19.9%、+40.8%、+2.1%，EPS分别为1.2元、1.8元、1.8元，对应H股PE分别 为15X/11X/11X，H股估值偏低，看好其长期发展，维持"买进"的投资评级。 群益证券主要观点如下： 公司控股子公司复宏汉霖授予日本卫材Eisai(东京交易所上市，代码4523.T)于日本用于肿瘤适应症治疗 的开发、生产及商业化斯鲁利单抗注射液的权利。根据约定，Eisai应就许可产品向复宏汉霖支付至多 15501万美元不可退还的首付款、监管里程碑款项，其中首付款7500万美元，至多8001万美元监管里程 碑付款。此外，公司还将基于许可区域日本年度的净销额达成情况，至多获得23333万美元的销售里程 碑付款，并可基于产品销售额，获得双位元数比例的销售提成。 风险提示：新产品研发进度及销售不及预期，药品集采及国谈降价超预期，商誉减值风险。 新市场及新适应症持续开拓中 斯鲁利单抗联合化疗一线治疗ES-SCLC的美国桥接试验正在有序进行，在日本的桥接试验也在稳步 ...

Group 1 - The core viewpoint of the report is that Fosun Pharma (02196) is expected to achieve net profits of 3.32 billion yuan, 4.68 billion yuan, and 4.77 billion yuan from 2025 to 2027, with year-over-year growth rates of +19.9%, +40.8%, and +2.1% respectively, indicating a positive long-term outlook and a "buy" rating maintained by Yuanta Securities [1] - The company’s subsidiary, Fuhong Hanlin, has granted Eisai the rights for the development, production, and commercialization of the PD-1 monoclonal antibody, Surulitinib, in Japan, with a total upfront payment and milestone payments potentially reaching up to $155.01 million [1] - The upfront payment includes $75 million and up to $80.01 million in regulatory milestone payments, along with potential sales milestone payments of up to $23.33 million based on annual net sales in Japan [1] Group 2 - Surulitinib, a PD-1 monoclonal antibody developed by the company, was launched in China in March 2022 and is expected to generate revenue of 1.31 billion yuan in 2024, reflecting a year-over-year growth of +17.2% [2] - The product has received EU approval for first-line treatment of SCLC in February 2025, making it the first PD-1 monoclonal antibody approved in the EU for this indication, and has also been approved in several other countries, enhancing its international market presence [2] - The company is actively expanding into new markets and indications, with ongoing clinical trials for Surulitinib in various cancers and a new application for gastric cancer treatment expected to be accepted by the Chinese regulatory authority by December 2025 [3]

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

许可产品斯鲁利单抗注射液为集团自主研发的创新型抗PD-1单抗，已在多个国家和地区获批上市，并 且在中国境内的适应症包括多种类型的癌症。 根据协议，Eisai需向复宏汉霖支付至多1.55亿美元的不可退还首付款及监管里程碑款项，其中首付款为 7500万美元，监管里程碑款项可达8001万美元。此外，Eisai还需根据许可产品的年度净销售额向复宏汉 霖支付至多2.33亿美元的销售里程碑款项及特许权使用费。 近日，复星医药（600196）发布公告称，控股子公司复宏汉霖与Eisai签订《许可协议》，由复宏汉霖授 予Eisai于许可区域（即日本）及领域（即用于肿瘤适应症治疗）开发、生产及商业化斯鲁利单抗注射液 的权利。 ...